drugset / Trial / NCT00117871

Study With a Topical Gel to Treat Common Warts in Adults

NCT00117871

Phase 2 Completed 48 enrolled Graceway Pharmaceuticals, LLC
Non-randomizedSingle-groupSingle-blindTreatment

Summary

The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks. A second purpose is to evaluate the safety of the drug.

Timeline

Start
2004-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule Topical

Indications